-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652.O4.6 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: A Map for the Changing Landscape of Multiple Myeloma

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Genetic Disorders, genomics, Workforce, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Biological Processes, pathogenesis
Sunday, December 12, 2021: 9:30 AM-11:00 AM
A411-A412, Level 4, Building A (Georgia World Congress Center)
Moderators:
Irene M. Ghobrial, MD, Dana-Farber Cancer Institute and Jill Corre, Unite de Genomique du Myelome, IUC-T Oncopole
Disclosures:
Ghobrial: AbbVie, Adaptive, Aptitude Health, BMS, Cellectar, Curio Science, Genetch, Janssen, Janssen Central American and Caribbean, Karyopharm, Medscape, Oncopeptides, Sanofi, Takeda, The Binding Site, GNS, GSK: Consultancy.
9:30 AM

Marietta Truger1*, Stephan Hutter, PhD1*, Manja Meggendorfer, PhD1, K. Martin Kortuem, MD2*, Niroshan Nadarajah1*, Wencke Walter, PhD1*, Constance Baer, PhD1, Leo Rasche, MD2*, Wolfgang Kern, MD1, Torsten Haferlach, MD1, Hermann Einsele3 and Claudia Haferlach, MD1

1MLL Munich Leukemia Laboratory, Munich, Germany
2Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
3Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany

9:45 AM

Rie Nakamoto-Matsubara, MD, PhD1,2*, Valentina Nardi, MD1,3, Cristina Panaroni, PhD1,4, Keertik Fulzele, PhD1,2*, Tomoaki Mori, MD, PhD1,2*, Rakesh Verma, PhD1,2*, Andrew J. Yee, MD1,2, Andrew R. Branagan, MD, PhD1,2, Elizabeth O’Donnell, MD1,2* and Noopur S. Raje, MD1,2

1Harvard Medical School, Boston, MA
2Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
3Department of Pathology, Massachusetts General Hospital, Boston, MA
4Center for Multiple Myeloma, Massachusetts General Hospital - Cancer Center, Boston, MA

10:00 AM

Santiago Thibaud, MD1, Aaron Etra, MD2, Ryan Subaran, PhD3*, Zachry Soens, MS3*, Scott Newman, PhD3*, Rong Chen, PhD3*, Ajai Chari, MD4, Hearn Jay Cho, MD, PhD5,6, Sundar Jagannath4, Deepu Madduri, MD4, David T. Melnekoff, MS7*, Shambavi Richard6*, Joshua Richter, MD6, Larysa Sanchez, MD4, Kuan-lin Huang, PhD8*, Alessandro Lagana, PhD7*, Samir Parekh, MD6 and Kenan Onel, MD, PhD8

1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
2Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY
3Sema4, Stamford, CT
4Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
5Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
6Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
7Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
8Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

10:15 AM

Nathanael R Fillmore, PhD1,2,3*, Jennifer La, PhD3*, Julie Tsu-Yu Wu, MD, PhD4,5*, Westyn Branch-Elliman, MD2,3*, Linden Huhmann, PhD3*, Summer S Han, PhD4*, Giovanni Parmigiani, PhD1,6*, David P Tuck, MD3,7*, Mary Brophy, MD, MPH3,7*, Nhan V Do, MD3,7*, Albert Y Lin, MD4,5* and Nikhil C. Munshi, MD, PhD1,2,3

1Dana-Farber Cancer Institute, Boston, MA
2Harvard Medical School, Boston, MA
3VA Boston Healthcare System, Boston, MA
4Stanford University, Palo Alto, CA
5VA Palo Alto Healthcare System, Palo Alto, CA
6Harvard T.H. Chan School of Public Health, Boston, MA
7Boston University School of Medicine, Boston, MA

10:30 AM

William Pilcher, BSc1*, Beena E Thomas, Ph.D2,3*, Swati S Bhasin, PhD2,4, Reyka G Jayasinghe, PhD5,6*, Adeeb H Rahman, PhD7,8*, Seunghee Kim-Schulze, PhD9*, Edgar Gonzalez-Kozlova, PhD10*, Taxiarchis Kourelis, MD11, Madhav V Dhodapkar, MD12, Ravi Vij, MBBS13,14, Shaji K Kumar, MD11,15, Shaadi Mehr, PhD16*, Mark Hamilton, PhD17*, Hearn Jay Cho, MD, PhD18,19, Daniel Auclair, PhD19, David Avigan, MD20, Sacha Gnjatic, PhD7,21*, Li Ding, PhD22* and Manoj Bhasin, PhD4

1Emory University, Wallace H. Coulter Department of Biomedical Engineering, Atlanta, GA
2Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta, GA
3Emory School of Medicine, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
4Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
5McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO
6Department of Medicine, Washington University School of Medicine, Saint Louis, MO
7Mount Sinai School of Medicine, New York, NY
8Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY
9Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
10Department of Genetics and Genomics., Icahn School of Medicine at Mount Sinai, New York
11Division of Hematology, Mayo Clinic, Rochester, MN
12Winship Cancer Institute, Emory University, Atlanta, GA
13Washington University School of Medicine, Ballwin, MO
14Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
15Mayo Clinic, Rochester, MN
16Multiple Myeloma Research Foundation, Norwalk, CT
17The Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
18Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
19Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
20Beth Israel Deaconess Medical Center, Boston, MA
21Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY
22Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

10:45 AM

Nancy Gillis, PharmD, PhD1,2, Lauren C Peres, PhD, MPH3*, Christelle M Colin-Leitzinger, PhD3*, Mingxiang Teng, PhD4*, Raghunandan Reddy Alugubelli, MS5*, Gabriel De Avila, BS6*, Dongliang Du, PhD4*, Erin M Siegel, PhD, MPH3,6*, Jamie Teer, PhD4*, Oliver Hampton, PhD7*, Melissa Alsina, MD8, Jason Brayer, PhD, MD2, Brandon J. Blue, MD2, Ariosto Siqueira Silva, PhD9*, Rachid Baz, MD2*, Taiga Nishihori, MD10 and Kenneth H. Shain, MD, PhD2

1Department of Cancer Epidemiology, Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
3Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL
4Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL
5Collaborative Data Services Core, Moffitt Cancer Center, Tampa, FL
6Total Cancer Care Department, Moffitt Cancer Center, Tampa, FL
7Bioinformatics an Biostatistics Department, M2GEN, Tampa, FL
8Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
9Department of Cancer Physiology, Moffitt Cancer Center, Tampa, FL
10Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

*signifies non-member of ASH